Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Merck KGaA Q1 2025: Strong Earnings, Upward 2026 Guidance & RNA‑Therapeutic Pivot

Merck KGaA’s Q1 2025 earnings beat expectations, lifting 2026 revenue/EBITA forecasts. Strong demand for high‑purity synthetic intermediates fuels growth while a pending Silence Therapeutics acquisition signals a shift toward RNA‑based therapeutics.

Dr. Michael Chen

14/11/2026, 00:33

4 minutes to read

Pfizer Secures $1.5 Billion from Blackstone for Obesity Drug Berobenatide

Pfizer secures $1.5 B from Blackstone Life Sciences to advance Berobenatide, a long‑acting GLP‑1 obesity drug with dual‑indication potential for weight loss, knee OA, and OSA.

Dr. Michael Chen

13/11/2026, 22:30

4 minutes to read

Ranoluspec Gains EU Approval: Cost‑Effective Ranibizumab Biosimilar Launches November 2026

Ranoluspec, Sandoz’s new ranibizumab biosimilar, is EU‑approved and ready for launch in Nov 2026, offering comparable visual‑acuity results at 20‑30% lower cost.

Dr. Michael Chen

13/11/2026, 08:38

4 minutes to read

Roivant Sciences Files Rule 144 Equity Sales: Execs Sell Shares to Cover Taxes

Roivant Sciences’ 10 Nov 2026 Rule 144 filings detail senior‑executive share sales for tax compliance, showing transparent governance amid active biotech pipelines.

Dr. Michael Chen

13/11/2026, 05:34

5 minutes to read

How Novo Nordisk’s $200 Million Diabetes Donation and GLP‑1 Strategies Shape Global Weight‑Loss Markets

Discover how Novo Nordisk’s $200 M pledge to the World Diabetes Foundation and its strategic GLP‑1 weight‑loss plans shape global diabetes and obesity care, balancing philanthropy, safety, and market expansion.

Dr. Michael Chen

12/11/2026, 21:36

5 minutes to read

IncYTE Corp. Reports Insider Stock Trades, Highlights Routine Corporate Activity

IncYTE’s Nov. 2026 Form 4 reveals insider stock trades and option exercises—showing routine shareholder shifts, no major strategy change, but solid research‑services focus.

Dr. Michael Chen

12/11/2026, 17:20

4 minutes to read

Roivant Sciences Officers File Routine 144/A Sell‑to‑Cover Share Sales on 10‑Nov‑2026

Roivant Sciences officers sell shares via Form 144/A to cover tax withholding on vested awards—routine, policy‑driven, and not indicative of company changes.

Dr. Michael Chen

12/11/2026, 04:08

3 minutes to read

Danaher Corp. Insider‑Trading Filings: 10‑Nov 2026 Exec Sales Under Rule 144 & Form 4

Danaher’s 10 Nov 2026 filings reveal senior‑executive stock sales under Rule 144 and Form 4, showing timing and type of trades while keeping prices private.

Dr. Michael Chen

11/11/2026, 18:54

3 minutes to read

TEVA Executive Share Sale: Insider Move Amid Strong Immunology & Oncology Pipeline

TEVA’s executive shares sale reflects routine Rule 144 compliance while spotlighting its innovative pipeline in PAH, oncology, and asthma—showcasing investor confidence in future growth.

Dr. Michael Chen

11/11/2026, 04:06

4 minutes to read

Regeneron’s CIDEBsiRNA Phase‑1/2 Trial Shows 24% Liver Fat Drop in NAFLD Patients

Regeneron’s CIDEBsiRNA phase‑1/2 study shows a 24.7 % drop in liver fat and improved ALT with minimal side‑effects, hinting at a future breakthrough for NAFLD.

Dr. Michael Chen

10/11/2026, 22:20

4 minutes to read

Older articles